Analyst Research

Report Title Price
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Zacks Investment Research Inc.
$12.00
Provider: TheStreet.com Ratings
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Kamada announces preliminary results from Phase II/III pivotal trial in Europe and Canada


Friday, 16 May 2014 07:30am EDT 

Kamada Ltd:Announces preliminary top-line results from Phase II/III pivotal clinical trial in Europe and Canada of inhaled Alpha-1 Antitrypsin (AAT) therapy for the treatment of Alpha-1 Antitrypsin Deficiency. 

Company Quote

2370.0
-131.0 -5.24%
10:24am EDT